health
Safiglipron met HbA1c non-inferiority in phase 3 diabetes trial
In a 810-person phase 3 trial in China, all three safiglipron doses were non-inferior to dapagliflozin for HbA1c reduction at 32 weeks. The 90 mg dose also met a prespecified superiority criterion in a separate analysis, while gastrointestinal events and treatment discontinuations were more frequent with safiglipron.